MPL: A Potential Drug Target Or Biomarker (G4352)

Target Name: MPL

NCBI ID: G4352

Content of Review Report on MPL Target / Biomarker

MPL

MPL: A Potential Drug Target Or Biomarker

MPL (TPOR-HUMAN) is a protein that is expressed in human tissues and has been identified as a potential drug target or biomarker. The protein is encoded by the gene TPOR (Transient receptor potential cation channel subfamily 4 member 1), which is a gene that is expressed in many different tissues throughout the body.

TPOR is a protein that is characterized by its ability to regulate the movement of positively charged ions, also known as ions channels, into a cell. This process is important for many different cellular functions, including the regulation of muscle contractions, the sensation of pain and touch, and the regulation of blood pressure.

MPL is a protein that is similar to TPOR, but it is missing a portion of the TPOR protein. This missing portion is important for MPL's ability to function as a drug target or biomarker. MPL is expressed in many different tissues throughout the body, including the brain, heart, and kidneys, and it is involved in the regulation of a wide range of cellular processes.

One of the potential benefits of MPL as a drug target is its ability to modulate the activity of many different proteins. This makes it an attractive target for drugs that are designed to interfere with the function of these proteins. For example, MPL has been shown to play a role in the regulation of pain perception, and drugs that are designed to block its function may be effective in treating chronic pain.

MPL has also been shown to be involved in the regulation of the immune system. This makes it an attractive target for drugs that are designed to interfere with its function in order to treat autoimmune diseases. For example, MPL has been shown to play a role in the regulation of the production of immune cells, and drugs that are designed to block its function in this way may be effective in treating autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

Another potential benefit of MPL as a drug target is its ability to modulate the activity of the cell cycle. This makes it an attractive target for drugs that are designed to interfere with the function of cells in order to treat cancer. For example, MPL has been shown to play a role in the regulation of cell cycle progression, and drugs that are designed to block its function in this way may be effective in treating a variety of cancers.

In addition to its potential as a drug target, MPL is also a potential biomarker. This is because it is expressed in many different tissues throughout the body and can be used as a protein biomarker for a wide range of diseases. For example, MPL has been used as a biomarker for a variety of neurological and cardiovascular diseases, and it may be useful in the diagnosis and treatment of these conditions.

Overall, MPL is a protein that is expressed in many different tissues throughout the body and has been identified as a potential drug target or biomarker. Further research is needed to fully understand its function and potential as a drug.

Protein Name: MPL Proto-oncogene, Thrombopoietin Receptor

Functions: Receptor for thrombopoietin that acts as a primary regulator of megakaryopoiesis and platelet production. May represent a regulatory molecule specific for TPO-R-dependent immune responses

The "MPL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MPL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets